A Long-Term Safety Study of Once-Daily Travatan - Full Text View

A Long-Term Safety Study of Once-Daily Travatan

This study is ongoing, but not recruiting participants.

Sponsored by:	Alcon Research
Information provided by:	Alcon Research
ClinicalTrials.gov Identifier:	NCT00051168

Purpose

Long term safety study of TRAVATAN in patients with Open-angle glaucoma or ocular hypertension.

Condition	Intervention	Phase
Glaucoma, Open-Angle Ocular Hypertension	Drug: Travoprost (0.004%)	Phase III

Genetics Home Reference related topics:

early-onset glaucoma

MedlinePlus related topics:

Glaucoma High Blood Pressure

Drug Information available for:

Travoprost

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Official Title:	A Long-Term Safety Study of Once-Daily TRAVATAN

Further study details as provided by Alcon Research:

Study Start Date:	January 2006
Estimated Study Completion Date:	April 2009
Estimated Primary Completion Date:	April 2009 (Final data collection date for primary outcome measure)

Eligibility

Criteria

Adult patients of any race and either sex with chronic angle-closure glaucoma.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00051168

Locations


United States, Texas
	Europe
	Fort Worth, Texas, United States

Sponsors and Collaborators

Alcon Research

More Information

Study ID Numbers:	C-02-20
First Received:	January 3, 2003
Last Updated:	August 4, 2008
ClinicalTrials.gov Identifier:	NCT00051168
Health Authority:	United States: Food and Drug Administration

Keywords provided by Alcon Research:

Glaucoma

POAG

OAG

OHT

Study placed in the following topic categories:

Glaucoma

Eye Diseases

Glaucoma, Open-Angle

Vascular Diseases

Travoprost

Hypertension

Ocular Hypertension

Additional relevant MeSH terms:

Cardiovascular Diseases

ClinicalTrials.gov processed this record on November 20, 2008